Literature DB >> 3035515

Modulation of dopamine receptors by thyrotropin-releasing hormone in the rat brain.

K S Funatsu, K Inanaga.   

Abstract

Nanomolar concentration of thyrotropin-releasing hormone (TRH) in vitro caused a significant reduction of [3H]apomorphine binding sites (70% of the control) in the rat striatum and the limbic forebrain. [3H]Spiperone binding was not affected by TRH. On the other hand, dopamine and apomorphine displaced [3H]TRH binding partially, suggesting the presence of a TRH receptor subpopulation that has a high affinity for dopamine agonist. Most of the neuroleptics displaced [3H]TRH binding dose-dependently in the micromolar range. (-)-Sulpiride had no affinity to TRH receptors. These findings suggest that one of the important roles of TRH as a neuromodulator is to modulate receptors for classical neurotransmitters, and this receptor-receptor interaction may be of importance in explaining the well known stimulating effects of TRH on the dopaminergic system.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3035515     DOI: 10.1016/0196-9781(87)90107-0

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  3 in total

1.  Neuroleptic malignant syndrome and hypothyroidism.

Authors:  A P Moore; I A Macfarlane; L D Blumhardt
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-06       Impact factor: 10.154

2.  Neuroleptic malignant syndrome with thyroid disorder: An unusual case report.

Authors:  Fan Zhang; Parisa Kanzali; Vadim Rubin; Chris Paras; Joel Goldman
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

3.  Widening spectrum of neuroleptic malignant syndrome: Case series.

Authors:  Gunchan Paul; Sachi Singhal; Birinder S Paul; Gurparvesh Singh; Shriya Goyal
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2021-10-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.